Abbott Laboratories (ABT) reported a gross profit of $6.29 billion for the second quarter of the fiscal year, marking an 8.9% year-over-year increase. Gross margin improved by 79 basis points to 56.4%, influenced by higher-margin growth in its Medical Devices segment, particularly in diabetes care and structural heart products.
Key products driving this performance included the Libre CGM and the AVEIR leadless pacemaker. Abbott’s shares rose 16.8% in the past year, surpassing the industry average growth of 4.1% and the S&P 500’s 15.6% growth. The company’s current Price-to-Sales (P/S) ratio stands at 4.88X, below the industry average of 5.61X.
